FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2226-2227 May 24, 2007 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

Edited by Napoleone Ferrara. 280 pp., illustrated. Boca Raton, FL, CRC Press, 2007. $149.95. ISBN 978-0-8493-2844-2.

In 1989, two consecutive reports in Science described the cloning of vascular endothelial growth factor (VEGF) (the protein originally identified by Harold Dvorak and colleagues as vascular permeability factor), a landmark in the field of angiogenesis. Subsequent studies and clinical trials have since confirmed that VEGF is the dominant angiogenic factor in numerous diseases. Furthermore, numerous recent clinical trials have shown that the inhibition of VEGF can benefit patients with a variety of diseases in which angiogenesis has a role. Napoleone Ferrara, the editor of Angiogenesis, was an author of one of the 1989 reports in Science; his laboratory not . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.